Table 1. Patient characteristics.
| ID no. | Age | Rai stage | %CD5 CD19a | IgVHb | Chromosomal aberrationsc | Previous therapy | P53d |
|---|---|---|---|---|---|---|---|
| 1 | 76 | 1 | 95.7 | M | Del 11q22 | None | F |
| 2 | 50 | 1 | 90 | UM | Trisomy 12 | None | F |
| 3 | 63 | 2 | 89.6 | M | None | None | F |
| 4 | 52 | 0 | 86.2 | UM | Trisomy 12 | None | F |
| 5 | 66 | 0 | 86.2 | UM | ND | None | F |
| 6 | 72 | 0 | 99.8 | M | ND | None | F |
| 7 | 49 | 3 | 99.7 | M | ND | None | F |
| 8 | 74 | 0 | 96.2 | M | Del 13q14 | None | F |
| 9 | 53 | 2 | 81.8 | UM | Del 17p13 | Clb, FCO | F |
| 10 | 69 | 1 | 86.8 | UM | ND | FCR | F |
| 11 | 41 | 2 | 89 | M | Del 13q14 | Clb, F | F |
| 12 | 66 | 0 | 99.5 | UM | ND | None | F |
| 13 | 61 | 1 | 99.7 | M | ND | None | F |
| 14 | 76 | ND | 99.1 | M | ND | ND | F |
| 15 | 56 | ND | 99.3 | M | ND | ND | F |
| 16 | 60 | ND | 98.8 | M | ND | ND | F |
| 17 | 63 | 2 | 89.6 | M | None | Clb | F |
| 18 | 74 | 2 | 92.5 | M | ND | Clb | F |
| 19 | 59 | 4 | 100 | M | ND | None | F |
| 20 | 73 | 2 | 98.4 | UM | ND | None | F |
| 21 | 55 | ND | 93.8 | M | ND | ND | F |
| 22 | 59 | 2 | 92.3 | UM | Del 11q22 | Clb | F |
| 23 | 81 | ND | 93.3 | M | ND | ND | F |
| 24 | 60 | 0 | 99.2 | UM | ND | None | F |
| 25 | 75 | 0 | 94.6 | M | ND | ND | F |
| 26 | 51 | 2 | 79.9 | UM | Del 13q14 | Clb | F |
| 27 | 53 | 4 | 82.1 | UM | Del 11q22 | Clb, R-CHOP | F |
| 28 | 63 | 1 | 96.9 | M | None | None | F |
| 29 | 83 | 2 | 96.5 | M | ND | None | F |
| 30 | 47 | 0 | 87.5 | M | Del 13q14 | None | F |
| 31 | 86 | 2 | 81 | M | Del 13q14 | None | F |
| 32 | 68 | ND | 84.9 | UM | None | None | F |
| 33 | 73 | 2 | 98.4 | UM | ND | None | F |
| 34 | 61 | ND | 99.7 | UM | ND | ND | F |
| 35 | 74 | ND | 74.5 | ND | None | Clb | F |
| 36 | 55 | ND | 95.1 | UM | None | None | F |
| 37 | 41 | ND | 56.4 | UM | Del 17p13 | CVP, FCR, alemtuzumab, R-CHOP | D |
| 38 | 66 | 4 | 96.6 | M | Del 13q14 | Clb | F |
| 39 | 75 | ND | 82.9 | M | ND | ND | ND |
| 40 | 73 | ND | 96.4 | UM | ND | ND | ND |
Abbreviations: Clb, chlorambucil; F, fludarabine; FCO, fludarabine, cyclophosphamide, ofatumumab; FCR, fludarabine, cyclophosphamide, rituximab; ND, not determined; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone.
Percentage of cells positive for CD5/CD19 surface expression measured by FACS analysis.
Mutated IgVH gene (+) denotes >2% mutations compared with germline sequence.
As determined by FISH. Probes for 11q22.3 (ATM), centromere 12 (CEP12), 13q14 (D13S319), 14q32 (IGH) and 17p13 (TP53) were obtained from Abbot-Vysis. Samples with >10% aberrant signals were considered abnormal.
P53 functional status was measured via radiation-induced RNA expression of p53 target genes Puma and Bax as described previously F=p53 Functional, D=p53 Dysfunctional.